Skip to main content

Table 5 Patient activity as a proxy for survival: role of patient and institutional factors in CML patients (multivariate Cox model)

From: Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program

  

Hazard ratio

p-value

CI 95%

Patient covariates

   

 Age

<55y

1 (ref)

  
 

> = 55y

1.42

0.001

[1.16; 1.73]

 Initial phase

Chronic

1 (ref)

  
 

Accelerated form or blast crisis

4.16

<10-4

[1.87; 9.25]

Institutional covariates

   

 Research ability

 

0.55

0.01

[0.35; 0.86]

 Public institution

 

1.32

0.10

[0.95; 1.84]

 ≥1 hematologist or oncologist

 

0.88

0.73

[0.44; 1.79]

 Enrollment

<2 patients enrolled/y

1(ref)

  
 

[2–5] patients enrolled/y

0.69

0.09

[0.45; 1.07]

 

>5 patients enrolled/y

0.48

<10-4

[0.35; 0.67]

Interaction

    

Accelerated form * ≥1 hematologist or oncologist

0.43

0.05

[0.18; 0.99]

  1. Results in bold are statistically significant at the 5% level.
  2. Other non-significant covariates entered in the model: gender, institution's technical competency (bone marrow biopsy or aspiration, Ph + chromosome testing), number of physicians, WHO region.